

1 **Influence of social determinants of health on quality of life in** 2 **patients with multimorbidity**

3
4
5 José María Ruiz-Baena^{1¶}, Aida Moreno-Juste^{2,3,4¶*}, Beatriz Poblador-Plou^{2,4}, Marcos Castillo-
6 Jimena^{5,6,7}, Amaia Calderón-Larrañaga^{4,8}, Cristina Lozano-Hernández^{4,9,10}, Antonio Gimeno-
7 Miguel^{2,4} & Luis A Gimeno-Feliú^{2,3,4,11} & MULTIPAP GROUP[‡].

8
9 ¹ Preventive Medicine and Public Health Department, Virgen de la Victoria University
10 Hospital, Málaga, Spain

11 ² EpiChron Research Group, Aragon Health Sciences Institute (IACS), IIS Aragón, Miguel
12 Servet University Hospital, 50009 Zaragoza, Spain.

13 ³ San Pablo Primary Care Health Centre, Aragon Health Service (SALUD), 50003 Zaragoza,
14 Spain.

15 ⁴ Network for Research on Chronicity, Primary Care, and Health Promotion (RICAPPS),
16 Institute of Health Carlos III (ISCIII), 28029 Madrid, Spain.

17 ⁵ Department of Pharmacology and Paediatrics, School of Medicine, University of Malaga
18 (Universidad de Málaga). Málaga, Spain.

19 ⁶ Group C-08 Biomedical Research Institute of Málaga -IBIMA-, Málaga, Spain.

20 ⁷ Primary Care Health Centre Campillos, Northern Málaga Integrated Healthcare Area,
21 Andalusian Health Service, Campillos, Málaga, Spain.

22 ⁸ Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska
23 Institutet and Stockholm University, Stockholm, Sweden

24 ⁹ Research Unit, Primary Health Care Management Madrid, Madrid, Spain

25 ¹⁰ Biosanitary Research and Innovation Foundation of Primary Care (FIIBAP), Spain

26 ¹¹ Department of Medicine, Dermatology and Psychiatry, University of Zaragoza, 50009
27 Zaragoza, Spain.

28
29 *Corresponding autor

30 E-mail: aidamorenorej@gmail.com

31 [‡] Membership of the MULTIPAP GROUP is provided in the Acknowledgments

32 [¶] These authors contributed equally to this work.

33 [&] These authors also contributed equally to this work

34

35

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

36 **Abstract**

37 **Background**

38 Multimorbidity, especially among older patients, is one of the biggest challenges faced by modern
39 medicine, and is influenced by social determinants of health, giving rise to health inequalities in
40 the population. Here, we sought to determine the influence of social determinants of health on
41 quality of life in patients with multimorbidity.

42 **Methods and Materials**

43 This cross-sectional observational study included 573 patients aged 65–74 with multimorbidity
44 (≥ 3 diseases) and polypharmacy (≥ 5 drugs). Corresponding data was taken drawn from the
45 Spanish MULTIPAP study, and included social and demographic variables, and data on health-
46 related quality of life and overall self-perceived health status, assessed using the 5-level version
47 of the EuroQol 5-dimensional questionnaire (EQ-5D-5L). Descriptive, bivariate and multivariate
48 analyses with logistic regression models were performed.

49 **Results**

50 Mean patient age was 69.7 years, 55.8% of patients were female, 59.7% belonged to low social
51 classes (V, VI), a monthly income of 1051–€1850 predominated, and the median number of
52 diseases in the same patient was 6. Factors associated with higher quality of life were male gender
53 (OR=1.599, $p=0.013$), a higher educational level (OR=1.991, $p=0.036$), an absence of urban
54 vulnerability (OR=1.605, $p=0.017$), and the presence of medium social support (OR=1.689,
55 $p=0.017$). Having a higher number of diseases was associated with poorer quality of life
56 (OR=0.912, $p=0.017$).

57 **Conclusions**

58 Our findings describe associations between social determinants of health and quality of life in
59 patients aged 65–74 years with multimorbidity and polypharmacy. More illnesses, female gender,
60 a lower education level, urban vulnerability, and less social support are associated with poorer
61 quality of life, underscoring the need for a biopsychosocial approach in patient care.

62 **Keywords**

63 Social determinants of health, multimorbidity, quality of life, social support, primary healthcare

64

65 **Introduction**

66

67 The last century has seen an unprecedented increase in human life expectancy. Inherent to this
68 phenomenon is a parallel increase in the prevalence of chronic diseases for which old age is a key
69 risk factor, including hypertension, arthrosis, and diabetes [1].

70 Multimorbidity is defined as the coexistence of several chronic diseases in the same patient [2],
71 and affects an estimated 81.5% of individuals aged ≥ 85 years, 62% of those aged 65–74 years,
72 and 50% of those aged >65 years [3]. Coexistence of several chronic diseases is a very common
73 phenomenon, and has turned multimorbidity into one of the greatest challenges facing modern
74 healthcare systems.

75 Some studies have demonstrated exponential increases in disability when the number of chronic
76 diseases increases, and have characterized the effects of multimorbidity on health outcomes such
77 as physical functioning, mental health, and quality of life [4]. Health-related quality of life

78 (HRQoL) is a multi-dimensional concept used to examine the impact of health status on quality
79 of life, and can be measured in several ways, both objective and subjective. It also includes the
80 self-perception of the individual's living situation, and their attitudes towards modifying and
81 improving their conditions in relation to their goals, expectations, values and interests [5].

82 The mechanisms underlying multimorbidity are diverse and complex. On the one hand are
83 biological factors inherently related to the aging process itself, including gender, cellular
84 senescence, stem cell aging, and DNA methylation. On the other hand are factors such as lifestyle
85 (e.g., diet, sedentarism, sleep quality, use of harmful substances like alcohol or other drugs), social
86 and community-related variables (e.g., social support, loneliness, adverse childhood experiences),
87 and work conditions, all of which are conditioned by cultural, environmental and socio-economic
88 factors (urbanism, educational level) [6]. Although multimorbidity relates to the presence of
89 diseases, it should not be viewed solely from a biomedical perspective, and requires a
90 biopsychosocial, patient-focused approach. Primary care can play a central role in orchestrating
91 a multifactorial approach to the management of pluri-pathology, with the goal of maximizing
92 patient quality of life and minimizing potential morbidity and disability [7]. Considering how
93 social factors influence these variables is essential to help achieve this goal.

94 Social determinants of health (SDH) are defined as the conditions in which people are born, grow,
95 work, live, and age, including a combination of socio-economic, environmental, community and
96 work-related factors, apart from those related to healthcare systems. Historically, SDH have been
97 one of the main sources of societal inequities [8].

98 A better understanding of the relationship between SDH and health outcomes in older patients
99 with multimorbidity is essential to help improve quality of care of these patients. The aim of this
100 study was to examine how SDH influence quality of life in primary care patients aged 65–74 with
101 multimorbidity.

102 **Materials and Methods**

103 **Design and setting of the study**

104 We conducted a descriptive cross-sectional study using baseline information recorded for
105 participants enrolled in the MULTIPAP cluster-randomized controlled trial (RCT), which sought
106 to improve drug prescription in young-old adults with multimorbidity and polypharmacy through
107 a complex intervention in primary care. A detailed description of the design, methods, and
108 intervention of the MULTIPAP trial has been published elsewhere [9].

109 Briefly, the MULTIPAP RCT involved the voluntary participation of 117 family physicians who
110 recruited a total of 573 patients from 38 Spanish primary care health centres in 3 different regions
111 (Andalucía, Madrid, and Aragón) between November 8, 2016, and January 31, 2017 [10]. Patients
112 were randomly included in the study if they were aged 65–74 years, had multimorbidity (defined
113 as the presence of 3 or more chronic diseases) and polypharmacy (defined as taking 5 or more
114 different drugs during the preceding 3 months), had visited their family doctor at least once in the
115 preceding year, and were able to follow the study requirements. Institutionalized patients and
116 those with a life expectancy of less than 12 months and/or with a disease that in their physician's
117 opinion would not allow them to follow the study requirements were excluded. The recruiting
118 physicians provided the patient with detail information about the study, they confirmed the
119 patient's eligibility and obtained the patient's written informed consent.

120 This study was approved by the Clinical Research Ethics Committees of Aragón (CEICA,
121 PI15/0217) and was favourably evaluated by the Research Ethics Committee of the Province of
122 Malaga and by the Central Committee of Primary Care Research of the Community of Madrid.

123 **Study variables**

124 All data were obtained through face-to-face surveys during baseline patient consultations and
125 recorded using an electronic case report form. The information recorded for each patient is
126 indicated below.

127 Independent variables included for each patient were as follows: date of birth; gender; nationality;
128 marital status; family composition; housing indicators; self-perceived disturbances in the
129 neighbourhood; social class, divided into 6 categories from I (highest) to VI (lowest) according
130 to the Spanish 2017 National Health Survey and then dichotomized into high (I through IV) and
131 low (V and VI); educational level according to the Spanish 2011 Statistical Office's Population
132 and Housing Census questionnaire [11]; occupation according to the Spanish Classification of
133 Occupations CNO-11 [12]; socioeconomic status assessed based on monthly net income per
134 household, expressed as multiples of the minimum wage; self-perceived social support measured
135 using the Spanish version of the Duke Unc-11 Functional Social Support (DUFSS) questionnaire
136 [13]; and the number of chronic conditions registered in the patient's electronic health records.

137 Health-related quality of life and overall self-perceived health status, measured using the 5-level
138 version of the EuroQol 5-dimensional questionnaire (EQ-5D-5L), was assessed as a dependent
139 variable. The EQ-5D-5L considers 5 dimensions (mobility, self-care, daily activities,
140 pain/discomfort, and anxiety/depression), and requires patients to rate their level of impairment
141 for each item (5 levels, from 1 [no problems] to 5 [being unable to do/having extreme problems]).
142 According to the responses to each item, an overall index score (ranging from 0–1) was calculated
143 for each patient using the EQ-5D-5L Crosswalk Index Value Calculator. This calculator is
144 available on the EuroQol website and provides validated results for the Spanish population
145 obtained from a matrix of transition probabilities between health states [14].

146 **Statistical analysis**

147 We described the characteristics of the study population as frequencies and/or the mean and
148 standard deviation (sd). Subsequently, we analysed the distribution of patient quality of life
149 according to the study variables. The Kolmogorov-Smirnov test indicated that quality of life
150 followed a non-normal distribution. Therefore, the Mann Whitney U-test and the Kruskal-Wallis
151 test were used for comparisons between 2 and >2 groups, respectively. In the case of the Kruskal-
152 Wallis test, the Dwass-Steel-Critchlow-Fligner post-hoc test was performed for all variables for
153 which statistical significance was found, to determine the specific pairs of variables for which the
154 differences were significant. Results were expressed as the median and corresponding
155 interquartile range (IQR).

156 Finally, we conducted a multivariate analysis to test the association between independent study
157 variables and patient quality of life, using a logistic regression model for the EQ-5D-5L scale. To
158 this end, the EQ-5D-5L variable was transformed into a dichotomised variable with 2 possible
159 outcomes (low/high), depending on whether the patient's score was below or above the median,
160 respectively. This categorization was performed to obtain homogeneous groups.

161 All statistical analyses were conducted in STATA software (Version 17.0, StataCorp LLC,
162 College Station, TX, USA) and Jamovi (Version 2.3.5) [17].

163 **Results**

164 The main sociodemographic characteristics of the study population are shown in Table 1. Mean
165 age was 69.7 years, and 55.8% of patients were women. A large portion of the sample (59.7%)
166 corresponded to low social classes (V, VI). Monthly income was classified as medium (defined
167 as a monthly salary of €1051–€1850) in the largest proportion of patients (42.6%). Finally, the
168 median number of diseases in the same patient was 6 (IQR 4–7).

169

170 **Table 1.** Main sociodemographic characteristics of the study population

n	573
Age (mean (SD))	69.69 (2.68)
Gender = Female (%)	320 (55.8)
Nationality = Spanish (%)	564 (98.4)
Marital status (%)	
Married	433 (75.6)
Separated	27 (4.7)
Single	23 (4.0)
Widower	90 (15.7)
Educational level (%)	
Did not complete primary studies	264 (46.1)
Completed primary studies	235 (41.0)
Degree or higher	74 (12.9)
Occupation (%)	
Elementary occupations	223 (38.9)
Essential sectors	241 (42.1)
Technicians, office employment	109 (19.0)
Social class (%)	
I - Professional occupations	35 (6.1)
II - Managerial and technical occupations	26 (4.5)
III - Skilled non-manual occupations	75 (13.1)
IV - Skilled manual occupations	95 (16.6)
V - Partly skilled manual occupations	205 (35.8)
VI - Unskilled manual occupations	137 (23.9)
Monthly income (%)	
Low - ≤€1050	163 (28.4)
Medium - €1051–€1850	244 (42.6)
High - ≥€1851	145 (25.3)
Unknown	21 (3.7)
Home size (m ²), mean (SD)	94.03 (43.39)
Lives alone = Yes (%)	101 (17.6)
Number of cohabitants, mean (SD)	2.30 (0.68)
Urban vulnerability ¹ = Yes (%)	203 (35.6)
EQ-5D-5L, mean (SD)	0.77 (0.20)
Functional social support, mean (SD)	43.82 (8.75)
Number of diseases, median [IQR]	6.00 [4.00, 7.00]

¹Patients reported having problems with at least 4 of the 9 items assessed

171

172 The results of a univariate analysis of the relationship between independent variables (analysed
173 separately) and quality of life are shown in Table 2. Median quality of life was lower in women
174 versus men; in patients from a low versus high social class; in patients in a situation of urban
175 vulnerability; in patients with a low versus high monthly income; in patients with a lower
176 educational level; and in patients with a lower level of social support.

Table 2. Quality of life (EQ-5D-5L) distribution according to social determinants of health: results of a univariate analysis

Variable	Median [IQR]	p-value
Gender		<0.001
Female	0.790 [0.659–0.887]	
Male	0.857 [0.744–0.911]	
Social class		0.005
Low (I–IV)	0.799 [0.662–0.910]	
High (V–VI)	0.838 [0.737–0.924]	
Lives alone		0.244
Yes	0.800 [0.653–0.910]	
No	0.818 [0.694–0.910]	
Urban vulnerability¹		<0.001
Yes	0.769 [0.642–0.887]	
No	0.838 [0.711–0.910]	
Monthly income		0.004 ²
Low ≤€1050	0.799 [0.641–0.893]	
Medium €1051–1850	0.818 [0.694–0.910]	
High ≥€1851	0.846 [0.743–0.932]	
Educational level		0.005 ³
Did not complete primary studies	0.818 [0.692–0.910]	
Completed primary studies	0.800 [0.662–0.910]	
Degree or higher	0.877 [0.781–0.932]	
Occupation		0.075
Elementary occupations	0.817 [0.662–0.910]	
Essential sectors	0.818 [0.694–0.910]	
Technicians, office employments	0.841 [0.723–0.932]	
Marital status		0.083
Married	0.818 [0.699–0.910]	
Separated	0.756 [0.649–0.910]	
Single	0.781 [0.682–0.921]	
Widower	0.809 [0.600–0.857]	
Social support		<0.001 ⁴
Lower tertile	0.784 [0.649–0.874]	
Medium tertile	0.857 [0.740–0.919]	
Higher tertile	0.818 [0.694–0.910]	

1. Patients reported having problems with at least 4 of the 9 items assessed

2. After applying the corresponding post-hoc pairwise comparison, significant differences were observed between the *Low* and *High* groups ($p = 0.003$)

3. After applying the corresponding post-hoc pairwise comparison, significant differences were observed between the groups *Did not complete primary studies* and *Degree or higher* ($p = 0.003$), as well as *Completed primary studies* and *Degree or higher* ($p = 0.01$)

4. After applying the corresponding post-hoc pairwise comparison, significant differences were observed between the *Lower tertile* and *Medium tertile* groups ($p < 0.001$)

178

179

180 Table 3 shows the results of a multivariate analysis that examined the association between quality
181 of life and several social variables. The analysis identified the following statistically significant
182 risk factors for worse quality of life (odds ratio [OR], p-value): female sex (OR=1.599, p=0.013);
183 lower versus higher educational level (OR=1.991, p=0.036); a situation of urban vulnerability
184 (OR=1.605, p=0.017); and low versus medium level of social support (OR=1.689, p=0.017).
185 Furthermore, a higher number of diseases was associated with worse quality of life (OR=0.912,
186 p=0.017).

187

Table 3. Association between quality of life (EQ-5D-5L) and variables related to social determinants of health (multivariate analysis)

Predictor	OR	95% CI		p-value
		Lower	Upper	
Number of diseases	0.912	0.846	0.984	0.017
Gender				
Female	(ref)			
Male	1.599	1.104	2.317	0.013
Social class				
Low (I–IV)	(ref)			
High (V–VI)	1.101	0.737	1.646	0.638
Urban vulnerability¹				
Yes	(ref)			
No	1.605	1.103	2.335	0.013
Monthly income				
Low ≤€1050	(ref)			
Medium €1051–1850	0.989	0.645	1.516	0.960
High ≥€1851	1.240	0.729	2.107	0.427
Educational level				
Did not complete primary studies	(ref)			
Completed primary studies	0.856	0.577	1.271	0.442
Degree or higher	1.991	1.048	3.783	0.036
Social support				
Lower tertile	(ref)			
Medium tertile	1.689	1.096	2.601	0.017
Higher tertile	0.948	0.598	1.504	0.822

Note. Estimates represent the log odds of "QoL EQ-5D-5L = High" vs. "QoL EQ-5D-5L = Low"

¹ Referred as having problems with at least 4 of the 9 items assessed

188

189

190 Discussion

191

192 Main findings

193 We observed significant associations between several of the SDH studied and quality of life in
194 patients aged 65–74 with multimorbidity and polypharmacy. Specifically, the following
195 independent variables were correlated with poorer quality of life: female gender; lower
196 educational level; living in a neighbourhood in a situation of urban vulnerability; a lower level of
197 social support; and a higher number of concomitant diseases.

198 **Comparison with other studies**

199 While the literature highlights the importance of studying the influence of SDH on quality of life,
200 data on this association in patients with multimorbidity are scarce. Lawson et al. [18] investigated
201 the relationship between multimorbidity and quality of life using a score that combined both
202 physical and mental health function, based on data collected in the Scottish Health Survey. In line
203 with the present findings, those authors observed an association between poorer quality of life
204 and (i) increasing number of comorbid diseases and (ii) greater economic deprivation. In contrast
205 to our findings, they detected no significant influence of sex on quality of life.

206 Von dem Knesebeck et al. [19] also analysed the association between socioeconomic status and
207 patient-reported outcomes, including HRQoL, in a cohort of patients aged 65–85 with
208 multimorbidity. Among the socioeconomic variables studied, a correlation was found between a
209 lower monthly income and poorer health status, in agreement with the present findings. However,
210 the authors reported no significant correlations between health status and either occupation or
211 educational level.

212 Park et al. [20] used the EQ-5D-5L scale to measure QoL in older patients, and observed that
213 female sex and lower socioeconomic level were significantly associated with a lower EQ-5D-5L
214 score. Another study of the relationship between educational level and quality of life [21] reported
215 significant associations between worse quality of life and both low educational level and lower
216 monthly income.

217 Greater feelings of loneliness have been related to poorer quality of life in elderly patients with
218 multimorbidity [22]. Specifically, feeling of loneliness were found to influence the
219 psychophysical health of elderly individuals. While the present study did not include any variables
220 related to social loneliness, we observed a correlation between a lower level of social support and
221 poorer quality of life.

222 As stated above, few studies have analysed the relationship between multimorbidity, SDH, and
223 quality of life, highlighting the need for greater research in this area to better understanding the
224 underlying contributing factors and the types of interventions required to address multimorbidity.
225 Older patients with low socioeconomic status experience a ‘double burden of disease’. They are
226 at higher risk of multimorbidity and, compared with matched patients with a higher
227 socioeconomic status, are worse off in terms of key outcomes such as functional status, health
228 related quality of life, and self-rated health [19]. In addition, the relationship between
229 socioeconomic factors and quality of life is influenced by psychosocial factors including self-
230 efficacy, coping behaviours, social contacts, social support, and psychosocial stress; behavioural
231 factors such as activity level, smoking, and alcohol consumption; and material factors including
232 living conditions [19]. Although supporting scientific evidence is limited, interventions targeting
233 psychosocial and lifestyle-related factors, applied at the patient level, could help minimize
234 multimorbidity [6]. A clinical trial is currently underway in Ireland to evaluate the effectiveness
235 of social interventions at the primary care level on patients’ health in disadvantaged areas of the
236 country [23].

237 SDH are undoubtedly key contributors to social inequity, which in turn arise as a consequence of
238 sociopolitical and socioeconomic factors. They also generate vulnerabilities that affect all aspects
239 of the individual’s life, including health [24]. Moreover, synergies between different factors can
240 exponentially increase the risk of multimorbidity, beyond their expected additive effects [25].

241 One such example is the association between lower quality of life and both socioeconomic level
242 and deprivation index: this relationship is influenced by multiple factors, one of which is the
243 “inverse care law” [26,27]. This law reflects the fact that health service availability does not
244 correspond to the greater needs of disadvantaged populations, resulting in insufficient health
245 resources to manage patients' conditions. Furthermore, this effect can be exacerbated by the fact
246 that disadvantaged social groups often have reduced personal capacity, community support [18],
247 and access to healthy food [20], factors that could potentially mitigate the impact of
248 multimorbidity.

249 Knowledge of the influence of social variables on health behaviours, and consideration by
250 healthcare providers of patients' socioeconomic context, health-related quality of life, and
251 preferences, can help ensure a more effective approach to the management of multimorbidity.
252 Understanding of factors that influence quality of life can enable implementation of strategic
253 measures based on SDH. Consideration of quality of life as perceived by the patient is also
254 important to improve the care of elderly patients with multimorbidity, and to facilitate
255 individualized therapy and increased involvement in self-care.

256 **Strengths and weaknesses**

257 A key strength of this study is the use of data derived from a multicentre study in which primary
258 care professionals participated. The availability of these data enabled a broader assessment of
259 participating patients, including data relating to a range of psychosocial variables that are
260 frequently omitted from such studies (e.g. quality of life, social support, and urban vulnerability).

261 Limitations of this study are those intrinsically related to the measurement of social variables.
262 Subjectivity in responses can lead to a higher degree of interpatient variability. Furthermore, it is
263 difficult to separately analyse closely interrelated variables that are ultimately part of larger,
264 multidimensional concepts. To maximise internal validity, we used the version of the DUFSS
265 questionnaire validated for use in non-institutionalized elderly individuals [13], a population that
266 closely corresponds to that of the present study.

267 Measurement of variables that may affect quality of life is important, as poorer self-perceived
268 quality of life can be associated with poorer adherence to treatment, which in turn is related
269 to greater urban vulnerability and lower functional support [28]. Other independent variables that
270 may be related to quality of life but that were not considered in our analysis include psychosocial
271 factors such as self-efficacy, coping behaviour, social contacts, social support, and psychosocial
272 stress, and behavioural factors such as physical activity, smoking, and alcohol consumption [19].

273 Lastly, limiting the study to patients aged 65–74 with multimorbidity can result in a loss of
274 external validity if the results are extrapolated to the rest of the population. However, the
275 population aged 65–74 corresponds to an increasingly larger stratum of the population, not only
276 in Spain but in developed countries in general [29]. Furthermore, the large sample size and the
277 fact that this study was conducted via coordinated efforts in 3 different regions in Spain lend
278 greater validity to our findings in terms of potential for extrapolation to the broader population in
279 this age range.

280 **Conclusion**

281 Our findings showed the association between SDH and quality of life in patients aged 65–74 with
282 multimorbidity and polypharmacy. A greater number of illnesses, female gender, lower
283 educational level, urban vulnerability, and reduced social support were all identified as variables
284 associated with poorer quality of life in this population, underscoring the need for a
285 biopsychosocial approach to the care of these patients. Consideration by healthcare professional
286 of the socioeconomic context, quality of life, and living conditions of these patients can help
287 ensure a more effective approach to the management of multimorbidity.

288

289 Acknowledgments

290 The authors thank all healthcare professionals and patients from the Primary Healthcare Centres
291 that participated in this study.

292 MULTIPAP GROUP:

293 **Lead authors for the MULTIPAP Study group:** Alexandra Prados Torres (Aragonese Institute
294 of Health Sciences (IACS), IIS Aragón, Miguel Servet University Hospital, Spain)
295 sprados.iacs@aragon.es, Juan Daniel Prados Torres (Multiprofessional Teaching Unit for Family
296 and Community Care Primary Care District Málaga-Guadalupe. Málaga)
297 juand.prados.sspa@juntadeandalucia.es, Isabel del Cura (Research unit. Primary Health Care
298 Management Madrid. Spain) isabel.cura@salud.madrid.org.
299

300 Coordinating Committee

301 Mercedes Aza-Pascual-Salcedo (EpiChron Research Group, Aragon Health Sciences Institute
302 (IACS), IIS Aragón, RICAPPS ISCIII, Aragon Health Service (SALUD), Zaragoza, Spain),
303 Antonio Gimeno-Miguel (EpiChron Research Group, Aragon Health Sciences Institute (IACS),
304 IIS Aragón, RICAPPS ISCIII, Miguel Servet University Hospital, Zaragoza, Spain), Francisca
305 González Rubio (EpiChron Research Group, Aragon Health Sciences Institute (IACS), IIS
306 Aragón, RICAPPS ISCIII, Zaragoza, Spain), Cristina M Lozano Hernández (Research unit.
307 Primary Health Care Management Madrid. Spain), Juan A. López-Rodríguez (Research unit.
308 Primary Health Care Management Madrid. Spain, RICAPPS ISCIII), Beatriz Poblador-Plou
309 (EpiChron Research Group, Aragon Health Sciences Institute (IACS), IIS Aragón, RICAPPS
310 ISCIII, Miguel Servet University Hospital, Zaragoza, Spain), Francisca Leiva Fernández
311 (Multiprofessional Teaching Unit for Family and Community Care Primary Care District Málaga-
312 Guadalhorce. Málaga, RICAPPS ISCIII), Fernando López-Verde (Las Delicias Health Center
313 (Centro de Salud las Delicias), Málaga-Guadalupe Health District, Málaga, Spain), Victoria
314 Pico-Soler (EpiChron Research Group, Aragon Health Sciences Institute (IACS), IIS Aragón,
315 RICAPPS ISCIII, Aragon Health Service (SALUD), Zaragoza, Spain), Ma Josefa Bujalance-
316 Zafra (La Victoria Health Center (Centro de Salud la Victoria), Málaga-Guadalupe Health
317 District, Málaga, Spain), Luis A. Gimeno-Feliu (EpiChron Research Group, Aragon Health
318 Sciences Institute (IACS), IIS Aragón, RICAPPS ISCIII, Aragon Health Service (SALUD),
319 Zaragoza, Spain), Marisa Rogero-Blanco (Instituto de Investigación Sanitaria Gregorio Marañón
320 IISGM, RICAPPS ISCIII, Ricardos General Health Center, Madrid, Spain), Francisca García-de-
321 Blas (Dr Mendiguchia Carriche Health Center, RICAPPS ISCIII Madrid, Spain), Marcos Castillo
322 Jimena (Coín Health Center, Málaga-Guadalupe Health District, Málaga, Spain;), Marcos
323 Alonso-García (Preventive Medicine Unit, University Hospital Alcorcón Foundation, Madrid,
324 Spain), Alessandra Marengoni (Department of Clinical and Experimental Sciences, University of
325 Brescia, Brescia, Italy), Jesús Martín Fernández (Multiprofessional Teaching Unit for Family and
326 Community Care, Primary Healthcare Centre (PHC) Oeste, Madrid, Spain), Elena Polentinos
327 Castro (Research unit. Primary Health Care Management Madrid. Spain), José María Valderas
328 Martínez (National University of Singapore, RICAPPS ISCIII), María del Pilar Barnestein-
329 Fonseca (CUDECA Foundation, Biomedical Research Institute of Málaga –IBIMA, Malaga
330 University, Spain), Miguel Domínguez-Santaella (PHC Victoria, Malaga-Guadalupe Health
331 District, Andalusian Health Service, Malaga, Spain), Nuria García-Agua-Soler (Department of
332 Pharmacology, Faculty of Medicine, Malaga University, Spain), María Isabel Márquez-Chamizo
333 (PHC Carranque, Malaga-Guadalupe Health District, Andalusian Health Service, Málaga,
334 Spain), José María Ruiz-San-Basilio (PHC Coín, Malaga-Guadalupe Health District,
335 Andalusian Health Service, Coín, Málaga, Spain), José María Abad-Díez (Lozano Blesa Hospital,
336 Zaragoza, Spain), Marta Alcaraz Borrajo (Subdirectorato General of Pharmacy and Health

337 Products), Gloria Ariza Cardiel (Multiprofessional Teaching Unit for Family and Community
338 Care Primary Care PHC Oeste, Madrid, Spain), Amaya Azcoaga Lorenzo (PHC Pintores, Madrid,
339 Spain), Marta Alcaraz Borrajo (Subdirectorate General of Pharmacy and Health Products), Ana
340 Cristina Bandrés-Liso (EpiChron Research Group, Aragon Health Sciences Institute (IACS), IIS
341 Aragón, RICAPPS ISCIII, Aragon Health Service (SALUD), Zaragoza, Spain), Amaia Calderon-
342 Larrañaga (EpiChron Research Group, Aragon Health Sciences Institute (IACS), IIS Aragón,
343 RICAPPS ISCIII, Zaragoza, Spain), Aging Research Center, Department of Neurobiology, Care
344 Sciences and Society, Karolinska Institute, Stockholm University, Stockholm, Sweden) Mercedes
345 Clerencia-Sierra (EpiChron Research Group, Aragon Health Sciences Institute (IACS), IIS
346 Aragón, RICAPPS ISCIII, Miguel Servet University Hospital, Aragon Health Service (SALUD),
347 Zaragoza, Spain), Javier Marta-Moreno (IIS Aragón, Miguel Servet University Hospital, Aragon
348 Health Service (SALUD), Zaragoza, Spain), Christiane Muth (Department of General Practice
349 and Family Medicine, Medical Faculty OWL, University of Bielefeld, Germany), Antonio
350 Poncel-Falcó (EpiChron Research Group, Aragon Health Sciences Institute (IACS), IIS Aragón,
351 RICAPPS ISCIII, Aragon Health Service, Zaragoza, Spain), Ana Isabel González González
352 (Technical Support Unit, Primary Care Management, Madrid Health Service), Virginia
353 Hernández Santiago (Ninewells Hospital & Medical School, Dundee, UK), Angel Mataix
354 SanJuan (Subdirectorate General of Pharmacy and Health Products, Madrid, Spain), Ricardo
355 Rodríguez Barrientos (Research unit. Primary Health Care Management, Madrid, Spain),
356 Mercedes Rumayor Zarzuelo (Public Health Centre Coslada, Área II Subdirectorate of Prevention
357 and Health Promotion, Madrid, Spain), Luis Sánchez Perruca (General System Information
358 Management, Primary Healthcare Management, Madrid Health Service, Spain), Teresa Sanz
359 Cuesta (Research unit. Primary Health Care Management Madrid. Spain), María Eugenia Tello
360 Bernabé (PHC El Naranjo, Madrid, Spain).

361

362 Clinical Investigators in Primary Healthcare Centres (PHC) MULTIPAP 363 GROUP:

364 **Andalucía, Spain: PHC Alhaurín el Grande** (Alhaurín el Grande): Javier Martín Izquierdo,
365 Macarena Toro Sainz. **PHC Carranque** (Málaga): María José Fernández Jiménez, Esperanza
366 Mora García, José Manuel Navarro Jiménez. **PHC Ciudad Jardín**, (Málaga): Leovigildo Ginel
367 Mendoza, Luz Pilar de la Mota Ybancos, Jaime Sasporte Genafó. **PHC Coín**, (Málaga): María
368 José Alcaide Rodríguez, Elena Barceló Garach, Beatriz Caffarena de Arteaga, María Dolores
369 Gallego Parrilla, Catalina Sánchez Morales. **PHC Delicias**, (Málaga): María del Mar Loubet
370 Chasco, Irene Martínez Ríos, Elena Mateo Delgado. **PHC La Roca**, (Málaga): Esther Martín
371 Auriolos. **PHC Limonar**, (Málaga): Sylvia Hazañas Ruiz. **PHC Palmilla**, (Málaga): María
372 Auxiliadora Nieves Muñoz Escalante. **PHC Puerta Blanca**, (Málaga): Enrique Leonés Salido,
373 María Antonia Máximo Torres, María Luisa Moya Rodríguez, María Encarnación Peláez Gálvez,
374 José Manuel Ramírez Torres, Cristóbal Trillo Fernández. **PHC Tiro Pichón**, (Málaga): María
375 Dolores García Martínez Cañavate, María del Mar Gil Mellado, María Victoria Muñoz Pradilla.
376 **PHC Vélez Sur** (Vélez Málaga): María José Clavijo Peña, José Leiva Fernández, Virginia
377 Castillo Romero. **PHC Vera**, (Vera, Almería): Rubén Vázquez Alarcón. **PHC Victoria**,
378 (Málaga): Rafael Ángel Maqueda, Gloria Aycart Valdés, Ana María Fernández Vargas, Irene
379 García, Antonia González Rodríguez, María Carmen Molina Mendaño, Juana Morales Naranjo,
380 Francisco Serrano Guerra.

381 **Aragón, Spain: PHC Alcorisa**, (Alcorisa, Teruel): Carmen Sánchez Celaya del Pozo. **PHC**
382 **Delicias Norte**, (Zaragoza): José Ignacio Torrente Garrido, Concepción García Aranda, Marina
383 Pinilla Lafuente, M^a Teresa Delgado Marroquín. **PHC Picarral**, (Zaragoza): M^a José Gracia
384 Molina, Javier Cuartero Bernal, M^a Victoria Asín Martín, Susana García Domínguez. **PHC**
385 **Fuentes de Ebro**, (Zaragoza): Carlos Bolea Gorbea. **PHC Valdefierro**, (Zaragoza): Antonio Luis
386 Oto Negre. **PHC Actur Norte**, (Zaragoza): Eugenio Galve Royo, M^a Begoña Abadía Taira. **PHC**

387 **Alcañiz**, (Teruel): José Fernando Tomás Gutiérrez. **PHC Sagasta - Ruiseñores**, (Zaragoza): José
388 Porta Quintana, Valentina Martín Miguel, Esther Mateo de las Heras, Carmen Esteban Algora.
389 **PHC Ejea** (Ejea de los Caballeros, Zaragoza): María Teresa Martín Nasarre de Letosa, Elena
390 Gascón del Prim, Noelia Sorinas Delgado, María Rosario Sanjuan Cortés. **PHC Canal Imperial**
391 **- Venecia**, (Zaragoza): Teodoro Corrales Sánchez. **PHC Canal Imperial - San José Sur**,
392 (Zaragoza): Eustaquio Dendarieta Lucas. **PHC Jaca** (Jaca, Huesca): María del Pilar Mínguez
393 Sorio. **PHC Santo Grial**, (Huesca): Adolfo Cajal Marzal.

394 **Madrid, Spain: PHC Mendiguchía Carriche** (Leganés): Francisca García De Blas González
395 Eduardo Díaz García, Juan Carlos García Álvarez, Cristina Guisado Pérez, Alberto López García
396 Franco, Maria Elisa Viñuela Benitez. **PHC El Greco** (Getafe): Ana Ballarín González, Maria
397 Isabel Ferrer Zapata, Esther Gómez Suarez, Fernanda Morales Ortiz, Lourdes Carolina Peláez
398 Laguno, José Luis Quintana Gómez, Enrique Revilla Pascual. **PHC Cuzco** (Fuenlabrada): M
399 Ángeles Miguel Abanto. **PHC El Soto** (Móstoles): Blanca Gutiérrez Teira, **PHC General**
400 **Ricardos** (Madrid): Francisco Ramón Abellán López, Carlos Casado Álvaro, Paulino Cubero
401 González, Santiago Manuel Machín Hamalainen, Raquel Mateo Fernández, Cesar Sánchez Arce.
402 **PHC Ibiza** (Madrid): Jorge Olmedo Galindo. **PHC Las Américas** (Parla): Claudia López
403 Marcos, Soledad Lorenzo Borda, Juan Carlos Moreno Fernández, Belén Muñoz Gómez, Enrique
404 Rodríguez De Mingo. **PHC María Ángeles López** (Leganés): Juan Pedro Calvo Pascual,
405 Margarita Gómez Barroso, Beatriz López Serrano, María Paloma Morso Peláez, Julio Sánchez
406 Salvador, Jeannet Dolores Sánchez Yépez, Ana Sosa Alonso. **PHC M^a Jesús Hereza** (Leganés):
407 María del Mar Álvarez Villalba. **PHC Pavones** (Madrid): Purificación Magán Tapia. **PHC Pedro**
408 **Lain Entralgo** (Alcorcón): María Angélica Fajardo Alcántara, María Canto De Hoyos Alonso,
409 María Aránzazu Murciano Antón. **PHC Pintores** (Parla): Manuel Antonio Alonso Pérez, Ricardo
410 De Felipe Medina, Amaya Nuria López Laguna, Eva Martínez Cid De Rivera, Iliana Serrano
411 Flores, María Jesús Sousa Rodríguez. **PHC Ramón y Cajal** (Alcorcón): María Soledad Núñez
412 Isabel, Jesús M^a Redondo Sánchez, Pedro Sánchez Llanos, Lourdes Visedo Campillo.

413 **References**

- 414 1. Prados-Torres A, Poblador-Plou B, Calderón-Larrañaga A, Gimeno-Feliu L,
415 González-Rubio F, Poncel-Falcó A. Multimorbidity patterns in primary care:
416 Interactions among chronic diseases using factor analysis. *PLoS One*. 2012;7.
417 2. Van Den Akker M, Buntinx F, Knottnerus JA. Comorbidity or multimorbidity:
418 What's in a name? A review of literature. *Eur J Gen Pract*. 1996;2(2):65–70.
419 3. Salive ME. Multimorbidity in older adults. *Epidemiol Rev*. 2013 Jan
420 1;35(1):75–83.
421 4. Arokiasamy P, Uttamacharya U, Jain K, Biritwum RB, Yawson AE, Wu F, et al.
422 The impact of multimorbidity on adult physical and mental health in low- and
423 middle-income countries: what does the study on global ageing and adult health
424 (SAGE) reveal? *BMC Med*. 2015 Aug 3;13:178.
425 5. The World Health Organization Quality of Life (WHOQOL). Copenhagen,
426 2012. Available from: [https://www.who.int/publications/i/item/WHO-HIS-HSI-](https://www.who.int/publications/i/item/WHO-HIS-HSI-Rev.2012.03)
427 [Rev.2012.03](https://www.who.int/publications/i/item/WHO-HIS-HSI-Rev.2012.03)
428 6. Skou ST, Mair FS, Fortin M, Guthrie B, Nunes BP, Miranda JJ, et al.
429 Multimorbidity. *Nat Rev Dis Prim*. 2022 Jul 14;8(1):48.
430 7. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology
431 of multimorbidity and implications for health care, research, and medical
432 education: a cross-sectional study. *Lancet (London, England)*.
433 2012;380(9836):37–43.

- 434 8. Marmot M, Friel S, Bell R, Houweling TA, Taylor S. Closing the gap in a
435 generation: health equity through action on the social determinants of health.
436 Lancet (London, England). 2008;372(9650):1661–9.
- 437 9. Prados-Torres A, del Cura-González I, Prados-Torres D, López-Rodríguez JA,
438 Leiva-Fernández F, Calderón-Larrañaga A, et al. Effectiveness of an
439 intervention for improving drug prescription in primary care patients with
440 multimorbidity and polypharmacy: Study protocol of a cluster randomized
441 clinical trial (Multi-PAP project). *Implement Sci*. 2017 Apr 27;12(1).
442 10. Damiani G, Del Cura-González I, López-Rodríguez JA, Leiva-Fernández F,
443 Gimeno-Miguel A, Poblador-Plou B, et al. How to Improve Healthcare for
444 Patients with Multimorbidity and Polypharmacy in Primary Care: A Pragmatic
445 Cluster-Randomized Clinical Trial of the MULTIPAP Intervention. *J Pers Med*
446 2022, Vol 12, Page 752. 2022 May 6;12(5):752.
- 447 11. INEbase / Demografía y población /Cifras de población y Censos demográficos
448 /Censos de población y viviendas / Últimos datos [Internet]. Available from:
449 [https://www.ine.es/dyngs/INEbase/es/operacion.htm?c=Estadistica_C&cid=125](https://www.ine.es/dyngs/INEbase/es/operacion.htm?c=Estadistica_C&cid=1254736176992&menu=ultiDatos&idp=1254735572981)
450 [4736176992&menu=ultiDatos&idp=1254735572981](https://www.ine.es/dyngs/INEbase/es/operacion.htm?c=Estadistica_C&cid=1254736176992&menu=ultiDatos&idp=1254735572981)
- 451 12. INEbase / Clasificaciones estadísticas /Clasificaciones nacionales /Clasificación
452 Nacional de Ocupaciones. CNO / Últimos datos [Internet]. Available from:
453 [https://www.ine.es/dyngs/INEbase/es/operacion.htm?c=Estadistica_C&cid=125](https://www.ine.es/dyngs/INEbase/es/operacion.htm?c=Estadistica_C&cid=1254736177033&menu=ultiDatos&idp=1254735976614)
454 [4736177033&menu=ultiDatos&idp=1254735976614](https://www.ine.es/dyngs/INEbase/es/operacion.htm?c=Estadistica_C&cid=1254736177033&menu=ultiDatos&idp=1254735976614)
- 455 13. Ayala A, Rodríguez-Blázquez C, Frades-Payo B, Forjaz MJ, Martínez-Martín P,
456 Fernández-Mayoralas G, et al. Propiedades psicométricas del Cuestionario de
457 Apoyo Social Funcional y de la Escala de Soledad en adultos mayores no
458 institucionalizados en España. *Gac Sanit*. 2012 Jul;26(4):317–24.
- 459 14. Herdman M, Badia X, Berra S. El EuroQol-5D: una alternativa sencilla para la
460 medición de la calidad de vida relacionada con la salud en atención primaria.
461 *Atención Primaria*. 2001 Jan 1;28(6):425–9.
- 462 15. Ministerio de Fomento. Gobierno de España. Instituto Juan de Herrera DUYOT.
463 Análisis urbanístico de Barrios Vulnerables en España Sobre la Vulnerabilidad
464 Urbana. 2010. Available from:
465 [https://www.fomento.gob.es/nr/rdonlyres/c88db66d-8669-497c-bee4-](https://www.fomento.gob.es/nr/rdonlyres/c88db66d-8669-497c-bee4-442ae027e2fb/111287/sobre_vulnerabilidad.pdf)
466 [442ae027e2fb/111287/sobre_vulnerabilidad.pdf](https://www.fomento.gob.es/nr/rdonlyres/c88db66d-8669-497c-bee4-442ae027e2fb/111287/sobre_vulnerabilidad.pdf)
- 467 16. Broadhead WE, Gehlbach SH, de Gruy F V., Kaplan BH. The Duke-UNC
468 Functional Social Support Questionnaire. Measurement of social support in
469 family medicine patients. *Med Care*. 1988;26(7):707–21.
- 470 17. The jamovi project (2022). *jamovi* (Version 2.3) [Computer Software].
471 Retrieved from <https://www.jamovi.org>
- 472 18. Lawson KD, Mercer SW, Wyke S, Grieve E, Guthrie B, Watt GC, et al. Double
473 trouble: The impact of multimorbidity and deprivation on preference-weighted
474 health related quality of life a cross sectional analysis of the Scottish Health
475 Survey. *Int J Equity Health*. 2013 Aug 20;12(1):1–9.
- 476 19. Von Dem Knesebeck O, Bickel H, Fuchs A, Gensichen J, Höfels S, Riedel-
477 Heller SG, et al. Social inequalities in patient-reported outcomes among older
478 multimorbid patients - results of the MultiCare cohort study. *Int J Equity Health*.
479 2015 Feb 3;14(1):1–11.
- 480 20. Park B, Ock M, Lee HA, Lee S, Han H, Jo MW, et al. Multimorbidity and
481 health-related quality of life in Koreans aged 50 or older using KNHANES
482 2013-2014. *Health Qual Life Outcomes*. 2018 Sep 15;16(1):1–10.
- 483 21. Clay OJ, Perkins M, Wallace G, Crowe M, Sawyer P, Brown CJ. Associations
484 of Multimorbid Medical Conditions and Health-Related Quality of Life Among

- 485 Older African American Men. *J Gerontol B Psychol Sci Soc Sci*. 2018 Jan
486 11;73(2):258-266.
- 487 22. Vespa A, Spatuzzi R, Fabbietti P, Di Rosa M, Bonfigli AR, Corsonello A, et al.
488 Association between Sense of Loneliness and Quality of Life in Older Adults
489 with Multimorbidity. *Int J Environ Res Public Health*. 2023 Feb 1;20(3).
- 490 23. Kiely B, Clyne B, Boland F, O'Donnell P, Connolly D, O'Shea E, et al. Link
491 workers providing social prescribing and health and social care coordination for
492 people with multimorbidity in socially deprived areas (the LinkMM trial):
493 protocol for a pragmatic randomised controlled trial. *BMJ Open*. 2021 Feb
494 1;11(2):e041809.
- 495 24. Marmot M, Friel S, Bell R, Houweling TA, Taylor S. Closing the gap in a
496 generation: health equity through action on the social determinants of health.
497 *Lancet*. 2008;372(9650):1661–9.
- 498 25. Moreno-Juste A, Gimeno-Miguel A, Poblador-Plou B, Calderón-Larrañaga A,
499 Cano Del Pozo M, Forjaz MJ, et al. Multimorbidity, social determinants and
500 intersectionality in chronic patients. Results from the EpiChron Cohort. *J Glob*
501 *Health*. 2023 Feb 3;13:04014.
- 502 26. Tudor Hart J. THE INVERSE CARE LAW. *Lancet*. 1971 Feb
503 27;297(7696):405–12.
- 504 27. Mercer SW, Guthrie B, Furler J, Watt GCM, Hart JT. Multimorbidity and the
505 inverse care law in primary care. *BMJ*. 2012 Jul 28;344(7867).
- 506 28. Lozano-Hernández CM, López-Rodríguez JA, Leiva-Fernández F, et al. Social
507 support, social context and nonadherence to treatment in young senior patients
508 with multimorbidity and polypharmacy followed-up in primary care.
509 MULTIPAP Study. *PLoS One*. 2020;15(6):e0235148.
- 510 29. Hernández CM, López-Rodríguez JA, Leiva-Fernández F, et al. Social support,
511 social context and nonadherence to treatment in young senior patients with
512 multimorbidity and polypharmacy followed-up in primary care. MULTIPAP
513 Study. *PLoS One*. 2020;15(6):e0235148.

514

515

516 **Funding**

517 This study was funded by the Carlos III Institute of Health, Ministry of Science and Innovation
518 (Spain) (Grant Numbers PI15/00276, PI15/00572, PI15/00996); the European Regional
519 Development Fund (“A way to build Europe”); the Network for Research on Chronicity, Primary
520 Care, and Health Promotion (RICAPPS) awarded as part of the call for the creation of Health
521 Outcomes-Oriented Cooperative Research Networks (grant number RD21/0016/0019,
522 RD21/0016/0015 and RD21/0016/0027); the Gobierno de Aragón (grant number B01_23R); and
523 co-funded with European Union’s NextGenerationEU funds.

524 **Competing interests**

525 The authors declare no competing interests.

526 **Data availability**

527 The Aragon Ethics Committee approved this research without considering the option of data
528 sharing. The data include sensitive clinical information about patients, and there are therefore

529 ethical and legal restrictions to sharing the data set. The data are part of the MULTIPAP study
530 and can be requested by contacting the Aragon Ethics Committee at the email
531 address ceica@aragon.es. Data can also be requested by contacting the Primary Care
532 Management of Madrid at the email address gap@salud.madrid.org, and the Technical Direction
533 of Teaching and Research at the email address dtdei@salud.madrid.org. The MULTIPAP Group
534 may establish future collaborations with other groups based on the same data. Data will be
535 available from the authors upon reasonable request and with permission of the project's principal
536 investigators (Alexandra Prados-Torres: sprados.iacs@aragon.es; Daniel Prados-Torres:
537 juand.prados.sspa@juntadeandalucia.es; Isabel del Cura: isabel.cura@salud.madrid.org).
538 However, each new project based on these data must be first submitted to CEICA for approval.

539

540 **Ethics statement**

541 The trial was designed in accordance with the basic ethical principles of beneficence, autonomy,
542 non-maleficence and justice, and it was conducted in accordance with the rules of Good Clinical
543 Practice outlined in the Oviedo Convention (1997) and the most recent Declaration of Helsinki.
544 Written informed consent of patients was required. Data confidentiality and anonymity was
545 ensured, according to the provisions of Spanish Law 15/1999, both during the implementation
546 phase of the project and in any resulting presentations or publications.

547 This study, as well as the written model form, was approved by the Clinical Research Ethics
548 Committees of Aragón (CEICA, PI15/0217) and was favourably evaluated by the Research Ethics
549 Committee of the Province of Malaga and by the Central Committee of Primary Care Research
550 of the Community of Madrid.